NuvOx Pharma, LLC
NuvOx Therapeutics is dedicated to advancing life-saving oxygen therapeutics with a mission to reverse tissue hypoxia, which plays a significant role in various fatal diseases. The company is committed to patient safety and ensuring access to innovative oxygen-based treatments.
Industries
Nr. of Employees
small (1-50)
NuvOx Pharma, LLC
1635 E 18th Street, Tucson, Arizona 85719
Patents
Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
US-11304899-B2
View Details
Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
US-11304899-B2
View DetailsProducts
Intravenous perfluorocarbon emulsion oxygen therapeutic (investigational)
An investigational intravenous perfluorocarbon-based emulsion engineered to form nanodroplets after infusion, facilitating oxygen uptake in the lungs and offloading to hypoxic tissues; under preclinical and clinical evaluation for acute indications including stroke, tumor radiosensitization, respiratory distress/ARDS, myocardial infarction and hemorrhagic shock.
Intravenous perfluorocarbon emulsion oxygen therapeutic (investigational)
An investigational intravenous perfluorocarbon-based emulsion engineered to form nanodroplets after infusion, facilitating oxygen uptake in the lungs and offloading to hypoxic tissues; under preclinical and clinical evaluation for acute indications including stroke, tumor radiosensitization, respiratory distress/ARDS, myocardial infarction and hemorrhagic shock.
Services
Sponsorship, protocol execution and site coordination for investigator-initiated and company-sponsored clinical trials across neurological, oncological and respiratory indications.
Production of investigational intravenous emulsions in a GMP environment with ISO 5 cleanroom capability to support clinical supply and rapid iteration between development and manufacturing.
Collaboration with public agencies and academic sponsors to obtain grant funding and to enable multi-center clinical trials and preclinical assessment networks.
Sponsorship, protocol execution and site coordination for investigator-initiated and company-sponsored clinical trials across neurological, oncological and respiratory indications.
Production of investigational intravenous emulsions in a GMP environment with ISO 5 cleanroom capability to support clinical supply and rapid iteration between development and manufacturing.
Collaboration with public agencies and academic sponsors to obtain grant funding and to enable multi-center clinical trials and preclinical assessment networks.
Expertise Areas
- Clinical trial management
- Translational preclinical research
- Neuroprotection and stroke therapeutics
- Oncology radiosensitization and tumor hypoxia reversal
Key Technologies
- Perfluorocarbon emulsion-based oxygen delivery
- Nanodroplet-forming intravenous emulsions
- In vitro oxygen offloading and gas-transfer assays
- Comparative gas solubility and absorption testing
News & Updates
NuvOx announced that the first patient has been dosed for its EXTEND trials of NanO₂ for mild respiratory distress in Phase Ib and ARDS in Phase II Trials.
NuvOx Pharma’s technology, developed as a first-in-class therapeutic, has been featured in a prominent peer review journal.
NuvOx was awarded the TechConnect Defense Innovation Award based on the potential impact on national security.
NuvOx was honored with the AZBIO Fast Lane Award for achievements in the last 18 months.
The National Cancer Institute granted $3 million to NuvOx for a Phase II clinical trial in glioblastoma.
NuvOx announced that the first patient has been dosed for its EXTEND trials of NanO₂ for mild respiratory distress in Phase Ib and ARDS in Phase II Trials.
NuvOx Pharma’s technology, developed as a first-in-class therapeutic, has been featured in a prominent peer review journal.
NuvOx was awarded the TechConnect Defense Innovation Award based on the potential impact on national security.
NuvOx was honored with the AZBIO Fast Lane Award for achievements in the last 18 months.
The National Cancer Institute granted $3 million to NuvOx for a Phase II clinical trial in glioblastoma.